Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor.
about
Nonimmunologic targets of immunosuppressive agents in podocytesStructural basis for recognition of CD20 by therapeutic antibody RituximabCD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases.Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis.Autoantibodies recognizing the amino terminal 1-17 segment of CENP-A display unique specificities in systemic sclerosis.Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease.Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study.Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody.Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential.Novel human antibody therapeutics: the age of the Umabs.Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndromeRituximab treatment prevents the early development of proteinuria following pig-to-baboon xeno-kidney transplantation.Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis.Rituximab therapy in nephrotic syndrome: implications for patients' management.Podocyte directed therapy of nephrotic syndrome-can we bring the inside out?Regulatory T cells and minimal change nephropathy: in the midst of a complex network.Emerging Agents for the Management of Nephrotic Syndrome: Progress to Date.Immunological evaluation of predicted linear B-cell epitopes of human CD20 antigen.Podocytes from the diagnostic and therapeutic point of view.Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.Sphingomyelinase-like phosphodiesterase 3b mediates radiation-induced damage of renal podocytes.Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms.B cell-derived IL-4 acts on podocytes to induce proteinuria and foot process effacement.Rituximab and Therapeutic Plasma Exchange in Recurrent Focal Segmental Glomerulosclerosis Postkidney Transplantation.Translational Aspects of Sphingolipid Metabolism in Renal Disorders.Rituximab protects podocytes and exerts anti-proteinuric effects in rat adriamycin-induced nephropathy independent of B-lymphocytes.
P2860
Q26781358-42E95B3C-5DE8-45C0-8870-3C97405B6D34Q27644280-B723DD7D-36D5-47F1-9B35-0FAD631AF5F9Q30388433-C0AE4727-5254-479D-9027-6FAFC4DCBC88Q30541740-B0C6A902-0C80-45F6-84EB-7F11C4583A30Q34684413-1BC70005-6BF7-4C6C-89E4-131327949D8AQ36060142-1AC73F70-8105-41DD-B494-1B9D3FA2140CQ36741001-5DF07F0C-6A3A-43F3-9DCA-68280903F3B1Q37081981-BF6A0186-21B5-415C-9364-67009806F355Q37212371-2237B76E-5827-4260-8FBF-649D29E59B2AQ37243228-1622540B-3975-4B93-8546-0045111D6BDEQ37275486-BC103A79-D7EE-4A42-AD0B-84D8D4A63ECDQ37670308-303FDBEC-1673-4331-98ED-133C430A54CCQ37690559-87AB2684-818D-40D4-8D5E-A1889DB15D43Q38075787-05D08C69-68F9-4B09-89C3-319883C1CC7DQ38458152-F90A3DB9-DFE6-43F1-8C4E-BBAF9C053F3DQ38543132-75FB92D5-AB62-4EF4-86EE-E03E790CEC30Q38662074-7B08CA75-F131-4E29-BECF-98644279B0C0Q39166301-247A3B70-87C9-42FC-9E72-53FEB9E609FCQ39309473-55EB0B89-4B53-4256-84B6-2D51B62FA7EEQ41966195-346A7D57-B1EF-4AE5-AB52-F481EF9F8531Q42501631-091BEDE7-A164-4E09-A6E2-3CB727B2B720Q43249169-402E811F-2F6C-4A23-8774-5BE68045CBD2Q47384287-C9AD559D-501C-4737-A901-59E664E9607EQ47392476-1D3735F6-9ED1-4D33-BC74-B190683AAB3DQ49399657-C800FE32-D333-4E54-AAF7-8870D0F717F0Q53637511-520A1BF2-B59F-42D3-A345-2451EB721C83
P2860
Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Generation of biologically act ...... hosphodiesterase 3b precursor.
@ast
Generation of biologically act ...... hosphodiesterase 3b precursor.
@en
type
label
Generation of biologically act ...... hosphodiesterase 3b precursor.
@ast
Generation of biologically act ...... hosphodiesterase 3b precursor.
@en
prefLabel
Generation of biologically act ...... hosphodiesterase 3b precursor.
@ast
Generation of biologically act ...... hosphodiesterase 3b precursor.
@en
P1433
P1476
Generation of biologically act ...... hosphodiesterase 3b precursor.
@en
P2093
Franco Dammacco
Maria Antonietta Caragnano
P304
P356
10.1182/BLOOD-2005-04-1769
P407
P577
2005-10-13T00:00:00Z